Robert Bell
Company: Ascidian Therapeutics
Job title: Senior Vice President & Head of Research
Seminars:
Panel Discussion: Contesting the Viability of Viral Vectors for Gene Editing Delivery 9:45 am
Considering the off-target editing and immunogenicity of viral vectors and whether these bottlenecks are solvable Discussing the viability and reliability of self-inactivating viral vectors Understanding the effects of random incorporation of viral genetic components into the genome and continued expression of the gene editorRead more
day: Day Two
Optimizing Ocular Delivery to Accelerate In Vivo Therapy into the Clinic for Rare Retinal Disorders 2:45 pm
Assessing strategies to advance ocular gene editing delivery Understanding how the engineering differentiates from systemic delivery Addressing safety concernsRead more
day: Day One